Ashraf Warsi
Overview
Explore the profile of Ashraf Warsi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bazarbashi S, El Zawahry H, Owaidah T, AlBader M, Warsi A, Marashi M, et al.
J Blood Med
. 2024 Apr;
15:171-189.
PMID: 38686358
Venous thromboembolism is a leading cause of morbidity and mortality in patients with active cancer who require anticoagulation treatment. Choice of anticoagulant is based on careful balancing of the risks...
2.
Abdulla Alzahrani H, Warsi A, Mullah-Ali A, Alotaibi G, Abu-Riash M, Alshahrani M, et al.
Acta Haematol
. 2024 Apr;
148(1):91-104.
PMID: 38565097
Background: Hemophilia A presents a significant health challenge in the Gulf region, where it has an especially high prevalence. There are several unmet needs associated with the management of hemophilia...
3.
Warsi A, Alamoudi S, Alsuraihi A, Althobaiti M, Daghistani M, Samarin K, et al.
Am J Case Rep
. 2023 Mar;
24:e938488.
PMID: 36864712
BACKGROUND Breakpoint cluster region (BCR)-Abelson murine leukemia (ABL1) and Janus Kinase-2 (JAK2) mutations have been thought to be mutually exclusive in myeloproliferative neoplasms (MNPs), but recent data suggest that they...
4.
AlSheef M, Bazarbashi S, Warsi A, Alfraih F, Almoomen A, Osman A, et al.
TH Open
. 2023 Feb;
7(1):e14-e29.
PMID: 36751300
Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic...
5.
Owaidah T, Almomen A, Tarawah A, Warsi A, Alkasim F, Alzahrani H, et al.
Am J Blood Res
. 2022 Jul;
12(3):82-87.
PMID: 35873100
Introduction: Emicizumab is a bispecific monoclonal antibody with the ability to bridge FIXa and FX, mimic FVIII, and restore normal hemostasis in patients with hemophilia A. Moreover, substantial evidence has...
6.
Noor A, Khan M, Warsi A, Aseeri M, Ismail S
Saudi Pharm J
. 2021 Oct;
29(10):1173-1180.
PMID: 34703371
Introduction: Warfarin is the core component in the management of various thromboembolic disorders, which requires specialized expertise to optimize outcomes. There is limited data comparing a pharmacist vs. a haematologist-managed...
7.
Hafiz W, Alotaibi F, Alneefia R, Alghuraibi E, Basha Ahmed A, Warsi A
Cureus
. 2021 Sep;
13(8):e17072.
PMID: 34522550
Haematological and vascular features of dengue virus infection are common and vary from tiny skin haemorrhages to significant bleeding such as epistaxis, gastrointestinal bleeding and hematuria. Spontaneous splenic rupture has...
8.
Alsobhi E, Abrar M, Abdelaal M, Alsaeed A, Absi A, Alzahrani Z, et al.
Leuk Lymphoma
. 2014 Jun;
56(4):882-6.
PMID: 24956142
No study has been published yet in the Arab world regarding response and outcome of imatinib in patients with chronic myeloid leukemia (CML). This study evaluated a total of 122...